Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tyra Biosciences, Inc. - Common Stock (NQ:TYRA)

19.90 -0.04 (-0.20%)
Delayed Quote Updated: 11:37 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tyra Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Gapping stocks in Wednesday's session ↗
Via Chartmill
Top movers in Wednesday's pre-market session ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies. 
Via The Motley Fool
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally ↗
Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tyra Biosciences Narrows Loss in Q2 ↗
Via The Motley Fool
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why WaFd Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? ↗
Tyra Biosciences shares TYRA-300 Phase 1/2 data in metastatic urothelial cancer with 100% disease control at ≥90 mg doses and favorable safety. 
Via Benzinga
News headline image
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug ↗
Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial... 
Via Benzinga
News headline image
This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.